Cover Image
市場調查報告書

大腸癌:流行病學·基於患者的市場預測,治療流程,上市藥·開發平台藥物分析

Colorectal Cancer Forecast and Market Analysis to 2036

出版商 Datamonitor Healthcare 商品編碼 365178
出版日期 內容資訊 英文 650 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
大腸癌:流行病學·基於患者的市場預測,治療流程,上市藥·開發平台藥物分析 Colorectal Cancer Forecast and Market Analysis to 2036
出版日期: 2017年12月11日 內容資訊: 英文 650 Pages
簡介

本報告提供大腸癌治療藥市場相關調查分析,提供您市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

預測:大腸癌

  • 摘要整理
  • 市場概要·趨勢
  • 手法·市場定義
  • Avastin (bevacizumab)
  • CPP-1X (eflornithine/sulindac)
  • Cyramza (ramucirumab)
  • Erbitux (cetuximab)
  • Imprime PGG
  • Keytruda (pembrolizumab)
  • Lonsurf (trifluridine/tipiracil)
  • Masitinib
  • MGN1703 (lefitolimod)
  • Ofev (nintedanib)
  • OncoVAX
  • Stivarga (regorafenib)
  • TS-1 (gimeracil/oteracil potassium/tegafur)
  • Vectibix (panitumumab)
  • Xilonix
  • Zaltrap (aflibercept)
  • 1次調查手法

治療:美國·日本·EU5個國家的大腸癌

  • 摘要整理
  • 疾病定義·診斷
  • 患者區分
  • 目前治療選擇
  • I期·II期
  • III期
  • IV期
  • 調查手法

流行病學:美國·日本·EU5個國家的大腸癌

  • 摘要整理
  • 疾病定義
  • 全球變動
  • 危險因素
  • 資訊來源·手法
  • 預測
  • 流行病學者的考察
  • 優點·缺點
  • 參考文獻

上市藥:大腸癌

  • 摘要整理
  • 產品概要
  • 其他上市藥
  • 產品簡介:Avastin
  • 產品簡介:Camptosar
  • 產品簡介:Cyramza
  • 產品簡介:Eloxatin
  • 產品簡介:Erbitux
  • 產品簡介:Lonsurf
  • 產品簡介:Stivarga
  • 產品簡介:Vectibix
  • 產品簡介:Xeloda
  • 產品簡介:Zaltrap

開發平台:大腸癌

  • 摘要整理
  • 臨床實驗平台概要
  • 產品簡介 (後期) :CPP-1X/sulindac
  • 產品簡介 (後期) :Imprime PGG
  • 產品簡介 (後期) :Keytruda
  • 產品簡介 (後期) :MGN1703
  • 產品簡介 (後期) :Ofev
  • 產品簡介 (後期) :OncoVAX
  • 產品簡介 (後期) :Xilonix
  • 產品簡介 (後期) :masitinib

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC10877

Disease Overview

Colorectal cancer (CRC) is one of the "big four" tumor types, the third most common cancer to affect both men and women, and the third-leading cause of cancer-related death. The main differentiator between colon cancer and rectal cancer is the location of the primary tumor, but identical etiology and similar risk factors and symptoms mean that they are often grouped together. CRC is believed to arise as a result of interactions between inherited and environmental factors. Despite improved prognosis of CRC patients in the last decade following advances in treatment options, survival rates still lag behind those of breast and prostate cancer patients.

Market Snapshot

Avastin will remain the leading targeted therapy in the colorectal cancer market through to

2024. Avastin in combination with FOLFOX remains the most commonly prescribed first-line treatment for Stage IV disease.

As screening has not yet affected incidence rates, incident cases are predicted to increase between 2016 and

2036. Approved drugs seek label expansions to better compete as patent expiries threaten to erode branded sales of Avastin and Erbitux.

Pipeline candidates will pursue novel mechanisms of action to distinguish themselves in an increasingly crowded market.

CONTENTS

15 FORECAST: COLORECTAL CANCER IN THE US, JAPAN, AND 5EU (Published on 11 December 2017)

15 EXECUTIVE SUMMARY

16 RECENT FORECAST UPDATES

17 MARKET DYNAMICS

23 FORECAST AND FUTURE TRENDS

34 MARKET DEFINITION AND METHODOLOGY

42 PRIMARY RESEARCH METHODOLOGY

45 BIBLIOGRAPHY

50 PRODUCT PROFILE: AVASTIN

67 PRODUCT PROFILE (LATE STAGE): COTELLIC

81 PRODUCT PROFILE: CYRAMZA

95 PRODUCT PROFILE: ERBITUX

111 PRODUCT PROFILE: KEYTRUDA

125 PRODUCT PROFILE: LONSURF

139 PRODUCT PROFILE (LATE STAGE): ONCOVAX

150 PRODUCT PROFILE: OPDIVO

164 PRODUCT PROFILE: STIVARGA

180 PRODUCT PROFILE: TS-1

190 PRODUCT PROFILE (LATE STAGE): TECENTRIQ

204 PRODUCT PROFILE: VECTIBIX

223 PRODUCT PROFILE: ZALTRAP

235 PRODUCT PROFILE (LATE STAGE): BINIMETINIB

248 PRODUCT PROFILE (LATE STAGE): LEFITOLIMOD

263 PRODUCT PROFILE (LATE STAGE): MASITINIB

277 PRODUCT PROFILE (LATE STAGE): NAPABUCASIN

291 TREATMENT: COLORECTAL CANCER IN THE US, JAPAN, AND 5EU (Published on 25 August 2017)

291 EXECUTIVE SUMMARY

292 PRIMARY RESEARCH METHODOLOGY

294 DISEASE DEFINITION AND DIAGNOSIS

302 PATIENT SEGMENTATION

304 CURRENT TREATMENT OPTIONS

308 PRESCRIBING TRENDS

327 EPIDEMIOLOGY: COLORECTAL CANCER IN THE US, JAPAN, AND 5EU (Published on 31 July 2017)

327 EXECUTIVE SUMMARY

328 DISEASE BACKGROUND

332 SOURCES AND METHODOLOGY

349 FORECAST

380 EPIDEMIOLOGIST INSIGHT

385 STRENGTHS AND LIMITATIONS

389 APPENDIX: ADDITIONAL SOURCES

390 MARKETED DRUGS: COLORECTAL CANCER (Published on 11 December 2017)

390 EXECUTIVE SUMMARY

391 PRODUCT OVERVIEW

392 PRODUCT PROFILE: AVASTIN

409 PRODUCT PROFILE: CYRAMZA

423 PRODUCT PROFILE: ERBITUX

439 PRODUCT PROFILE: KEYTRUDA

454 PRODUCT PROFILE: LONSURF

468 PRODUCT PROFILE: OPDIVO

482 PRODUCT PROFILE: STIVARGA

498 PRODUCT PROFILE: TS-1

508 PRODUCT PROFILE: VECTIBIX

527 PRODUCT PROFILE: ZALTRAP

539 PIPELINE: COLORECTAL CANCER (Published on 11 December 2017)

539 EXECUTIVE SUMMARY

540 CLINICAL PIPELINE OVERVIEW

542 PRODUCT PROFILE (LATE STAGE): COTELLIC

556 PRODUCT PROFILE (LATE STAGE): ONCOVAX

567 PRODUCT PROFILE (LATE STAGE): TECENTRIQ

581 PRODUCT PROFILE (LATE STAGE): BINIMETINIB

594 PRODUCT PROFILE (LATE STAGE): ENCORAFENIB

608 PRODUCT PROFILE (LATE STAGE): LEFITOLIMOD

622 PRODUCT PROFILE (LATE STAGE): MASITINIB

636 PRODUCT PROFILE (LATE STAGE): NAPABUCASIN

LIST OF FIGURES

  • 17 Figure 1: Colorectal cancer - current and future market dynamics analysis
  • 18 Figure 2: Datamonitor Healthcare's assessment summary of key marketed and pipeline drugs for colorectal cancer
  • 24 Figure 3: Colorectal cancer sales across the US, Japan, and five major EU markets, by country, 2016-25
  • 38 Figure 4: Patient-based forecast methodology for colorectal cancer
  • 40 Figure 5: Price sources and calculations, by country
  • 57 Figure 6: Avastin for colorectal cancer - SWOT analysis
  • 58 Figure 94: Distribution of colon cancer and rectal cancer across the US, Japan, and five major EU markets, 2016-36
  • 59 Figure 8: Datamonitor Healthcare's drug assessment summary of Avastin for colorectal cancer
  • 61 Figure 9: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • 72 Figure 10: Cotellic for colorectal cancer - SWOT analysis
  • 73 Figure 11: Datamonitor Healthcare's drug assessment summary of Cotellic for colorectal cancer
  • 74 Figure 12: Datamonitor Healthcare's drug assessment summary of Cotellic for colorectal cancer
  • 76 Figure 13: Cotellic sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • 86 Figure 14: Cyramza for colorectal cancer - SWOT analysis
  • 88 Figure 95: Age-specific trends in incident cases of diagnosed colorectal cancer in the US, Japan, and five major EU markets by country, 2016-36
  • 90 Figure 16: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • 116 Figure 17: Keytruda for colorectal cancer - SWOT analysis
  • 117 Figure 18: Datamonitor Healthcare's drug assessment summary for Keytruda in colorectal cancer
  • 120 Figure 19: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • 132 Figure 97: Datamonitor Healthcare's drug assessment summary of Avastin for colorectal cancer
  • 144 Figure 98: Cyramza for colorectal cancer - SWOT analysis
  • 145 Figure 22: Datamonitor Healthcare's drug assessment summary of OncoVAX for colon cancer
  • 146 Figure 23: Datamonitor Healthcare's drug assessment summary of OncoVAX for colon cancer
  • 156 Figure 24: Datamonitor Healthcare's drug assessment summary of Opdivo for colorectal cancer
  • 165 Figure 102: Datamonitor Healthcare's drug assessment summary of Erbitux for colorectal cancer
  • 172 Figure 26: Datamonitor Healthcare's drug assessment summary of Stivarga for colorectal cancer
  • 176 Figure 103: Keytruda for colorectal cancer - SWOT analysis
  • 183 Figure 104: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • 195 Figure 106: Datamonitor Healthcare's drug assessment summary of Lonsurf for colorectal cancer
  • 206 Figure 108: Opdivo for colorectal cancer - SWOT analysis
  • 214 Figure 109: Datamonitor Healthcare's drug assessment summary of Opdivo for colorectal cancer
  • 215 Figure 110: Datamonitor Healthcare's drug assessment summary of Opdivo for colorectal cancer
  • 227 Figure 114: Datamonitor Healthcare's drug assessment summary of Stivarga for colorectal cancer
  • 230 Figure 115: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • 240 Figure 117: Datamonitor Healthcare's drug assessment summary of TS-1 in colorectal cancer
  • 253 Figure 119: Datamonitor Healthcare's drug assessment summary of Vectibix for colorectal cancer
  • 255 Figure 121: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • 266 Figure 121: Datamonitor Healthcare's drug assessment summary of Zaltrap for colorectal cancer
  • 268 Figure 122: Datamonitor Healthcare's drug assessment summary of Zaltrap for colorectal cancer
  • 269 Figure 122: Zaltrap sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • 282 Figure 41: Napabucasin for colorectal cancer - SWOT analysis
  • 286 Figure 124: Cotellic for colorectal cancer - SWOT analysis
  • 303 Figure 125: OncoVAX for colon cancer - SWOT analysis
  • 313 Figure 133: Datamonitor Healthcare's drug assessment summary for binimetinib in colorectal cancer
  • 315 Figure 134: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • 318 Figure 135: Encorafenib for colorectal cancer - SWOT analysis
  • 319 Figure 47: Top three regimens used for second-line treatment of Stage IV colorectal cancer patients, by country
  • 321 Figure 137: Datamonitor Healthcare's drug assessment summary for encorafenib in colorectal cancer
  • 322 Figure 49: Percentage of local relapse colorectal cancer patients receiving each treatment type, by country
  • 323 Figure 138: Encorafenib sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • 324 Figure 51: Percentage of distant relapse colorectal cancer patients receiving each treatment type, by country
  • 337 Figure 139: Lefitolimod for colorectal cancer - SWOT analysis
  • 343 Figure 139: Datamonitor Healthcare's drug assessment summary for lefitolimod in colorectal cancer
  • 362 Figure 145: Datamonitor Healthcare's drug assessment summary for napabucasin in colorectal cancer
  • 382 Figure 55: Age distributions at diagnosis of rectal cancer and colon cancer, 2016
  • 399 Figure 56: Avastin for colorectal cancer - SWOT analysis
  • 400 Figure 57: Datamonitor Healthcare's drug assessment summary of Avastin for colorectal cancer
  • 401 Figure 58: Datamonitor Healthcare's drug assessment summary of Avastin for colorectal cancer
  • 403 Figure 59: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • 414 Figure 60: Cyramza for colorectal cancer - SWOT analysis
  • 415 Figure 61: Datamonitor Healthcare's drug assessment summary of Cyramza for colorectal cancer
  • 416 Figure 62: Datamonitor Healthcare's drug assessment summary of Cyramza for colorectal cancer
  • 418 Figure 63: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • 429 Figure 64: Erbitux for colorectal cancer - SWOT analysis
  • 430 Figure 65: Datamonitor Healthcare's drug assessment summary of Erbitux for colorectal cancer
  • 431 Figure 66: Datamonitor Healthcare's drug assessment summary of Erbitux for colorectal cancer
  • 433 Figure 67: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • 444 Figure 68: Keytruda for colorectal cancer - SWOT analysis
  • 445 Figure 69: Datamonitor Healthcare's drug assessment summary for Keytruda in colorectal cancer
  • 446 Figure 70: Datamonitor Healthcare's drug assessment summary for Keytruda in colorectal cancer
  • 448 Figure 71: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • 459 Figure 72: Lonsurf for colorectal cancer - SWOT analysis
  • 460 Figure 73: Datamonitor Healthcare's drug assessment summary of Lonsurf for colorectal cancer
  • 461 Figure 74: Datamonitor Healthcare's drug assessment summary of Lonsurf for colorectal cancer
  • 463 Figure 75: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • 473 Figure 76: Opdivo for colorectal cancer - SWOT analysis
  • 474 Figure 77: Datamonitor Healthcare's drug assessment summary of Opdivo for colorectal cancer
  • 475 Figure 78: Datamonitor Healthcare's drug assessment summary of Opdivo for colorectal cancer
  • 477 Figure 79: Opdivo sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • 488 Figure 80: Stivarga for colorectal cancer - SWOT analysis
  • 489 Figure 81: Datamonitor Healthcare's drug assessment summary of Stivarga for colorectal cancer
  • 490 Figure 82: Datamonitor Healthcare's drug assessment summary of Stivarga for colorectal cancer
  • 492 Figure 83: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • 501 Figure 84: TS-1 for colorectal cancer - SWOT analysis
  • 502 Figure 85: Datamonitor Healthcare's drug assessment summary of TS-1 in colorectal cancer
  • 503 Figure 86: Datamonitor Healthcare's drug assessment summary of TS-1 in colorectal cancer
  • 505 Figure 87: TS-1 sales for colorectal cancer in Japan, 2016-25
  • 518 Figure 88: Vectibix for colorectal cancer - SWOT analysis
  • 519 Figure 89: Datamonitor Healthcare's drug assessment summary of Vectibix for colorectal cancer
  • 520 Figure 90: Datamonitor Healthcare's drug assessment summary of Vectibix for colorectal cancer
  • 522 Figure 91: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • 530 Figure 92: Zaltrap for colorectal cancer - SWOT analysis
  • 531 Figure 93: Datamonitor Healthcare's drug assessment summary of Zaltrap for colorectal cancer
  • 532 Figure 94: Datamonitor Healthcare's drug assessment summary of Zaltrap for colorectal cancer
  • 534 Figure 95: Zaltrap sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • 547 Figure 96: Cotellic for colorectal cancer - SWOT analysis
  • 548 Figure 97: Datamonitor Healthcare's drug assessment summary of Cotellic for colorectal cancer
  • 549 Figure 98: Datamonitor Healthcare's drug assessment summary of Cotellic for colorectal cancer
  • 551 Figure 99: Cotellic sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • 561 Figure 100: OncoVAX for colon cancer - SWOT analysis
  • 562 Figure 101: Datamonitor Healthcare's drug assessment summary of OncoVAX for colon cancer
  • 563 Figure 102: Datamonitor Healthcare's drug assessment summary of OncoVAX for colon cancer
  • 565 Figure 103: OncoVAX sales for colon cancer in the US, 2016-25
  • 572 Figure 104: Tecentriq for colorectal cancer - SWOT analysis
  • 573 Figure 105: Datamonitor Healthcare's drug assessment summary of Tecentriq for colorectal cancer
  • 574 Figure 106: Datamonitor Healthcare's drug assessment summary of Tecentriq for colorectal cancer
  • 576 Figure 107: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • 585 Figure 108: Binimetinib for colorectal cancer - SWOT analysis
  • 586 Figure 109: Datamonitor Healthcare's drug assessment summary for binimetinib in colorectal cancer
  • 587 Figure 110: Datamonitor Healthcare's drug assessment summary for binimetinib in colorectal cancer
  • 589 Figure 111: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • 599 Figure 112: Encorafenib for colorectal cancer - SWOT analysis
  • 600 Figure 113: Datamonitor Healthcare's drug assessment summary for encorafenib in colorectal cancer
  • 601 Figure 114: Datamonitor Healthcare's drug assessment summary for encorafenib in colorectal cancer
  • 603 Figure 115: Encorafenib sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • 613 Figure 116: Lefitolimod for colorectal cancer - SWOT analysis
  • 614 Figure 117: Datamonitor Healthcare's drug assessment summary for lefitolimod in colorectal cancer
  • 615 Figure 118: Datamonitor Healthcare's drug assessment summary for lefitolimod in colorectal cancer
  • 617 Figure 119: Lefitolimod sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • 627 Figure 120: Masitinib for colorectal cancer - SWOT analysis
  • 628 Figure 121: Datamonitor Healthcare's drug assessment summary for masitinib in colorectal cancer
  • 629 Figure 122: Datamonitor Healthcare's drug assessment summary for masitinib in colorectal cancer
  • 631 Figure 123: Masitinib sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • 641 Figure 124: Napabucasin for colorectal cancer - SWOT analysis
  • 642 Figure 125: Datamonitor Healthcare's drug assessment summary for napabucasin in colorectal cancer
  • 643 Figure 126: Datamonitor Healthcare's drug assessment summary for napabucasin in colorectal cancer
  • 645 Figure 127: Napabucasin sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • 345 Figure 139: Datamonitor Healthcare's drug assessment summary for lefitolimod in colorectal cancer345

LIST OF TABLES

  • 25 Table 1: Colorectal cancer sales across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 29 Table 2: PD-1/PD-L1 colorectal cancer drug sales across the US, Japan, and five major EU markets, by brand ($m), 2016-25
  • 31 Table 3: Colorectal cancer sales across the US, Japan, and five major EU markets, by brand and class ($m), 2016-25
  • 35 Table 4: Summary of drug classes and molecules included in Datamonitor Healthcare's colorectal cancer patient-based forecast
  • 41 Table 5: Exchange rates used for calculating prices
  • 43 Table 6: Medical oncologists and gastroenterologists surveyed for the colorectal cancer primary research study, 2016
  • 51 Table 7: Avastin drug profile
  • 52 Table 8: Overview of major approvals for Avastin in colorectal cancer
  • 53 Table 9: Avastin Phase III data in colorectal cancer
  • 62 Table 10: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 64 Table 11: Patients treated with Avastin across the US, Japan, and five major EU markets, by country, 2016-25
  • 68 Table 12: Cotellic drug profile
  • 69 Table 13: Cotellic Phase III trial in colorectal cancer
  • 71 Table 14: Cotellic early-phase data in colorectal cancer
  • 77 Table 15: Cotellic sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • 79 Table 16: Patients treated with Cotellic in the US and five major EU markets, by country, 2016-25
  • 81 Table 17: Cyramza drug profile
  • 83 Table 18: Cyramza Phase III data in colorectal cancer
  • 85 Table 19: Cyramza Phase I trials in colorectal cancer
  • 91 Table 20: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 93 Table 21: Patients treated with Cyramza across the US, Japan, and five major EU markets, by country, 2016-25
  • 95 Table 22: Erbitux drug profile
  • 96 Table 23: Overview of major approvals for Erbitux in colorectal cancer
  • 100 Table 102: Gender-specific incident cases of colon cancer in the US, Japan, and five major EU markets, by country, 2016
  • 103 Table 105: Incident cases of diagnosed rectal cancer in the US, Japan, and five major EU markets, by stage at diagnosis and country, 2016
  • 106 Table 26: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 108 Table 27: Patients treated with Erbitux across the US, Japan, and five major EU markets, by country, 2016-25
  • 112 Table 28: Keytruda drug profile
  • 113 Table 29: Keytruda Phase III trial in colorectal cancer
  • 115 Table 30: Keytruda early-phase data in colorectal cancer
  • 121 Table 31: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 123 Table 32: Patients treated with Keytruda across the US, Japan, and five major EU markets, by country, 2016-25
  • 126 Table 33: Lonsurf drug profile
  • 127 Table 34: Lonsurf Phase III data in colorectal cancer
  • 129 Table 35: Lonsurf Phase II trials in colorectal cancer
  • 135 Table 36: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 137 Table 37: Patients treated with Lonsurf across the US, Japan, and five major EU markets, by country, 2016-25
  • 140 Table 38: OncoVAX drug profile
  • 141 Table 39: OncoVAX Phase III trial in colon cancer
  • 143 Table 40: OncoVAX Phase III data in colon cancer
  • 148 Figure 99: Datamonitor Healthcare's drug assessment summary of Cyramza for colorectal cancer
  • 149 Table 42: Patients treated with OncoVAX in the US, 2016-25
  • 151 Table 43: Opdivo drug profile
  • 152 Table 44: Opdivo pivotal trial data in colorectal cancer
  • 154 Table 45: Opdivo early-phase trials in colorectal cancer
  • 159 Table 118: Erbitux Phase III data in colorectal cancer
  • 160 Table 47: Opdivo sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • 162 Table 48: Patients treated with Opdivo across the US and five major EU markets, by country, 2016-25
  • 167 Table 49: Stivarga pivotal trial data in colorectal cancer
  • 169 Table 50: Stivarga ongoing trials in colorectal cancer
  • 170 Table 120: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 177 Table 52: Patients treated with Stivarga across the US, Japan, and five major EU markets, by country, 2016-25
  • 180 Table 53: TS-1 drug profile
  • 182 Table 54: TS-1 pivotal trial data in colorectal cancer
  • 187 Table 55: TS-1 sales for colorectal cancer in Japan ($m), 2016-25
  • 188 Table 56: Patients treated with TS-1 in Japan, 2016-25
  • 191 Table 57: Tecentriq drug profile
  • 192 Table 58: Tecentriq Phase III trial in colorectal cancer
  • 194 Table 59: Tecentriq early-phase data in colorectal cancer
  • 200 Table 60: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • 202 Table 61: Patients treated with Tecentriq in the US and five major EU markets, by country, 2016-25
  • 204 Table 62: Vectibix drug profile
  • 207 Table 63: Vectibix pivotal trial data in colorectal cancer
  • 213 Table 64: Vectibix early-phase data in colorectal cancer
  • 481 Table 134: Patients treated with Opdivo across the US and five major EU markets, by country, 2016-25
  • 221 Table 66: Patients treated with Vectibix in the US, Japan, and five major EU markets, by country, 2016-25
  • 223 Table 67: Zaltrap drug profile
  • 225 Table 68: Zaltrap pivotal trial data in colorectal cancer
  • 236 Table 69: Binimetinib drug profile
  • 238 Table 70: Binimetinib Phase III data in colorectal cancer
  • 243 Table 142: Vectibix drug profile
  • 244 Table 72: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • 246 Table 73: Patients treated with binimetinib in the US and five major EU markets, by country, 2016-25
  • 249 Table 74: Lefitolimod drug profile
  • 250 Table 75: Lefitolimod Phase III trial in colorectal cancer
  • 252 Table 76: Lefitolimod Phase II data in colorectal cancer
  • 258 Table 77: Lefitolimod sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 261 Table 78: Patients treated with lefitolimod across the US, Japan, and five major EU markets, by country, 2016-25
  • 263 Table 79: Masitinib drug profile
  • 267 Table 80: Masitinib early-phase data in colorectal cancer
  • 273 Table 81: Masitinib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • 275 Table 82: Patients treated with masitinib across the US and five major EU markets, by country, 2016-25
  • 278 Table 83: Napabucasin drug profile
  • 279 Table 84: Napabucasin Phase III trial in colorectal cancer
  • 281 Table 85: Napabucasin Phase III data in colorectal cancer
  • 287 Table 86: Napabucasin sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 289 Table 87: Patients treated with napabucasin across the US, Japan, and five major EU markets, by country, 2016-25
  • 292 Table 88: Medical oncologists and gastroenterologists surveyed for the colorectal cancer primary research study, 2016
  • 297 Table 89: Colorectal cancer five-year survival rates, by stage at diagnosis
  • 302 Table 90: TNM classification, by stage at diagnosis
  • 305 Table 91: Leading treatments for colorectal cancer
  • 329 Table 92: Colorectal cancer site codes according to the International Classification of Diseases and Related Health Problems 10th Revision
  • 335 Table 93: Cancer registry databases used as a source of colorectal cancer incidence data, by country
  • 622 Table 178: Lefitolimod sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 355 Table 96: Incident cases of diagnosed colon cancer in the US, Japan, and five major EU markets, by country, 2016-36
  • 364 Table 97: Age-specific incident cases of diagnosed colorectal cancer in the US, Japan, and five major EU markets, by country, 2016
  • 367 Table 98: Gender-specific incident cases of diagnosed colorectal cancer in the US, Japan, and five major EU markets, by country, 2016
  • 369 Table 99: Gender-specific incident cases of colon cancer in the US, Japan, and five major EU markets, by country, 2016
  • 370 Table 100: Gender-specific incident cases of rectal cancer in the US, Japan, and five major EU markets, by country, 2016
  • 371 Table 101: Incident cases of diagnosed colorectal cancer in the US, Japan, and five major EU markets, by stage at diagnosis and country, 2016
  • 373 Table 102: Incident cases of diagnosed colon cancer in the US, Japan, and five major EU markets, by stage at diagnosis and country, 2016
  • 375 Table 103: Incident cases of diagnosed rectal cancer in the US, Japan, and five major EU markets, by stage at diagnosis and country, 2016
  • 377 Table 104: Incident cases of diagnosed metastatic (Stage IV) CRC in the US, Japan, and five major EU markets, by selected genetic mutations and country, 2016
  • 386 Table 105: Validation of forecast estimates against benchmark estimates
  • 391 Table 106: Profiled key marketed drugs for colorectal cancer
  • 393 Table 107: Avastin drug profile
  • 394 Table 108: Overview of major approvals for Avastin in colorectal cancer
  • 395 Table 109: Avastin Phase III data in colorectal cancer
  • 404 Table 110: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 406 Table 111: Patients treated with Avastin across the US, Japan, and five major EU markets, by country, 2016-25
  • 409 Table 112: Cyramza drug profile
  • 411 Table 113: Cyramza Phase III data in colorectal cancer
  • 413 Table 114: Cyramza Phase I trials in colorectal cancer
  • 419 Table 115: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 421 Table 116: Patients treated with Cyramza across the US, Japan, and five major EU markets, by country, 2016-25
  • 423 Table 117: Erbitux drug profile
  • 424 Table 118: Overview of major approvals for Erbitux in colorectal cancer
  • 426 Table 119: Erbitux Phase III data in colorectal cancer
  • 428 Table 120: Erbitux Phase III data in colorectal cancer
  • 434 Table 121: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 436 Table 122: Patients treated with Erbitux across the US, Japan, and five major EU markets, by country, 2016-25
  • 440 Table 123: Keytruda drug profile
  • 441 Table 124: Keytruda Phase III trial in colorectal cancer
  • 443 Table 125: Keytruda early-phase data in colorectal cancer
  • 449 Table 126: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 451 Table 127: Patients treated with Keytruda across the US, Japan, and five major EU markets, by country, 2016-25
  • 455 Table 128: Lonsurf drug profile
  • 456 Table 129: Lonsurf Phase III data in colorectal cancer
  • 458 Table 130: Lonsurf Phase II trials in colorectal cancer
  • 464 Table 131: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 466 Table 132: Patients treated with Lonsurf across the US, Japan, and five major EU markets, by country, 2016-25
  • 469 Table 133: Opdivo drug profile
  • 470 Table 134: Opdivo pivotal trial data in colorectal cancer
  • 472 Table 135: Opdivo early-phase trials in colorectal cancer
  • 478 Table 136: Opdivo sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • 480 Table 137: Patients treated with Opdivo across the US and five major EU markets, by country, 2016-25
  • 483 Table 138: Stivarga drug profile
  • 485 Table 139: Stivarga pivotal trial data in colorectal cancer
  • 487 Table 140: Stivarga ongoing trials in colorectal cancer
  • 493 Table 141: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 495 Table 142: Patients treated with Stivarga across the US, Japan, and five major EU markets, by country, 2016-25
  • 498 Table 143: TS-1 drug profile
  • 500 Table 144: TS-1 pivotal trial data in colorectal cancer
  • 505 Table 145: TS-1 sales for colorectal cancer in Japan ($m), 2016-25
  • 506 Table 146: Patients treated with TS-1 in Japan, 2016-25
  • 508 Table 147: Vectibix drug profile
  • 510 Table 148: Overview of major approvals for Vectibix in colorectal cancer
  • 511 Table 149: Vectibix pivotal trial data in colorectal cancer
  • 517 Table 150: Vectibix early-phase data in colorectal cancer
  • 523 Table 151: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 525 Table 152: Patients treated with Vectibix in the US, Japan, and five major EU markets, by country, 2016-25
  • 527 Table 153: Zaltrap drug profile
  • 529 Table 154: Zaltrap pivotal trial data in colorectal cancer
  • 535 Table 155: Zaltrap sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 537 Table 156: Patients treated with Zaltrap in the US, Japan, and five major EU markets, by country, 2016-25
  • 541 Table 157: Profiled pipeline products in development for colorectal cancer
  • 543 Table 158: Cotellic drug profile
  • 544 Table 159: Cotellic Phase III trial in colorectal cancer
  • 546 Table 160: Cotellic early-phase data in colorectal cancer
  • 552 Table 161: Cotellic sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • 554 Table 162: Patients treated with Cotellic in the US and five major EU markets, by country, 2016-25
  • 557 Table 163: OncoVAX drug profile
  • 558 Table 164: OncoVAX Phase III trial in colon cancer
  • 560 Table 165: OncoVAX Phase III data in colon cancer
  • 565 Table 166: OncoVAX sales for colon cancer in the US ($m), 2016-25
  • 566 Table 167: Patients treated with OncoVAX in the US, 2016-25
  • 568 Table 168: Tecentriq drug profile
  • 569 Table 169: Tecentriq Phase III trial in colorectal cancer
  • 571 Table 170: Tecentriq early-phase data in colorectal cancer
  • 577 Table 171: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • 579 Table 172: Patients treated with Tecentriq in the US and five major EU markets, by country, 2016-25
  • 582 Table 173: Binimetinib drug profile
  • 584 Table 174: Binimetinib Phase III data in colorectal cancer
  • 590 Table 175: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • 592 Table 176: Patients treated with binimetinib in the US and five major EU markets, by country, 2016-25
  • 595 Table 177: Encorafenib drug profile
  • 596 Table 178: Encorafenib Phase III data in colorectal cancer
  • 598 Table 179: Encorafenib Phase II data in colorectal cancer
  • 604 Table 180: Encorafenib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • 606 Table 181: Patients treated with encorafenib across the US and five major EU markets, by country, 2016-25
  • 609 Table 182: Lefitolimod drug profile
  • 610 Table 183: Lefitolimod Phase III trial in colorectal cancer
  • 612 Table 184: Lefitolimod Phase II data in colorectal cancer
  • 618 Table 185: Lefitolimod sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 620 Table 186: Patients treated with lefitolimod across the US, Japan, and five major EU markets, by country, 2016-25
  • 622 Table 187: Masitinib drug profile
  • 624 Table 188: Masitinib Phase III trial in colorectal cancer
  • 626 Table 189: Masitinib early-phase data in colorectal cancer
  • 632 Table 190: Masitinib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • 634 Table 191: Patients treated with masitinib across the US and five major EU markets, by country, 2016-25
  • 637 Table 192: Napabucasin drug profile
  • 638 Table 193: Napabucasin Phase III trial in colorectal cancer
  • 640 Table 194: Napabucasin Phase III data in colorectal cancer
  • 646 Table 195: Napabucasin sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 648 Table 196: Patients treated with napabucasin across the US, Japan, and five major EU markets, by country, 2016-25
Back to Top